Cwm LLC Raises Stock Position in Danaher Co. (NYSE:DHR)

Cwm LLC boosted its holdings in Danaher Co. (NYSE:DHR) by 0.2% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 19,113 shares of the conglomerate’s stock after buying an additional 45 shares during the period. Cwm LLC’s holdings in Danaher were worth $4,422,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. Wellington Management Group LLP increased its stake in Danaher by 18.6% in the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after buying an additional 3,905,449 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Danaher by 6.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 8,183,501 shares of the conglomerate’s stock worth $2,030,327,000 after buying an additional 502,868 shares in the last quarter. Northern Trust Corp increased its stake in Danaher by 1.7% in the 3rd quarter. Northern Trust Corp now owns 8,100,722 shares of the conglomerate’s stock worth $2,009,789,000 after buying an additional 134,905 shares in the last quarter. Flossbach Von Storch AG increased its stake in Danaher by 1.8% in the 4th quarter. Flossbach Von Storch AG now owns 4,601,351 shares of the conglomerate’s stock worth $1,064,477,000 after buying an additional 82,672 shares in the last quarter. Finally, Invesco Ltd. increased its stake in Danaher by 13.2% in the 3rd quarter. Invesco Ltd. now owns 4,070,455 shares of the conglomerate’s stock worth $1,009,880,000 after buying an additional 473,693 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Royal Bank of Canada raised their price objective on Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Barclays raised their price objective on Danaher from $240.00 to $260.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 10th. Raymond James raised their price objective on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Finally, Citigroup lifted their price target on Danaher from $255.00 to $280.00 and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Six research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $268.27.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 2,622 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total value of $636,280.74. Following the transaction, the senior vice president now directly owns 4,244 shares in the company, valued at approximately $1,029,891.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the transaction, the senior vice president now directly owns 38,102 shares in the company, valued at $9,601,704. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Georgeann Couchara sold 2,622 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the sale, the senior vice president now owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The disclosure for this sale can be found here. Insiders have sold 32,957 shares of company stock worth $8,265,802 in the last three months. Corporate insiders own 10.90% of the company’s stock.

Danaher Stock Up 7.2 %

NYSE:DHR opened at $253.11 on Wednesday. The company has a market cap of $187.44 billion, a price-to-earnings ratio of 39.61, a price-to-earnings-growth ratio of 3.95 and a beta of 0.83. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $259.00. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. The stock has a fifty day simple moving average of $248.95 and a 200-day simple moving average of $230.64.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.18. The business had revenue of $6.41 billion for the quarter, compared to the consensus estimate of $6.10 billion. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The company’s revenue for the quarter was down 10.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.87 EPS. Analysts anticipate that Danaher Co. will post 7.62 EPS for the current year.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Shareholders of record on Thursday, March 28th will be paid a $0.27 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.24. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date is Wednesday, March 27th. Danaher’s dividend payout ratio is currently 16.90%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.